BRIEF

on JP Jenkins Ltd (isin : GB00BPLKLR77)

Redx Pharma Unveils Promising Data for Zamaporvint in GI Cancer Trials

Redx Pharma has presented encouraging Phase 2 trial results for its investigational drug, zamaporvint (RXC004), at the ESMO GI Congress. Designed for genetically-selected MSS mCRC patients, zamaporvint demonstrated partial responses in about 30% of cases when combined with anti-PD-1 therapy, notably outperforming existing standards where anti-PD-1 alone fails.

The clinical-stage biotech company highlighted zamaporvint's potential in treating hard-to-treat gastrointestinal cancers by focusing on Wnt-ligand dependency in tumors. The study showed a disease control rate of 57%, offering a new avenue for patients with limited treatment options.

Zamaporvint's tolerable safety profile and observed efficacy, particularly in genetically-selected patient subsets, underscore its potential in combination therapies. These findings pave the way for its further development in this patient group, with Redx seeking partnerships to advance clinical trials.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all JP Jenkins Ltd news